 Immunovant’s first-generation FcRn inhibitor flunked a pair of phase 3 eye disease trials, appearing to end the last hopes of commercializing the drug. The company set out plans back in 2022 to assess the therapy, called batoclimab, in two late-stage studies of patients with thyroid eye disease (TED). 
Content mobilized by FeedBlitz RSS Services, the premium FeedBurner alternative. |
